Educational Disclaimer: This article is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified mental health professional with any questions you may have regarding a medical condition.
If you or someone you know is in crisis: Call or text 988 (Suicide & Crisis Lifeline, available 24/7). Text HOME to 741741 (Crisis Text Line). For medical emergencies, call 911.
Table of Contents
- What Is Treatment-Resistant Depression?
- Why Do Some People Have Treatment-Resistant Depression?
- Diagnosing the Root of Treatment Resistance
- Evidence-Based Treatment Options for TRD
- Emerging and Investigational Approaches
- What Does Recovery from TRD Look Like?
- Frequently Asked Questions
Treatment-resistant depression (TRD) is defined as major depressive disorder that has not responded adequately to at least two antidepressant trials of adequate dose and duration. It affects an estimated 30% of people diagnosed with major depressive disorder – and it is not a reflection of personal failure. TRD reflects the biological complexity of depression, not a lack of effort or commitment to getting well.
The critical message for people living with treatment-resistant depression is this: not responding to initial antidepressants is not the end of the road. There are now more evidence-based options for TRD than ever before, including FDA-approved treatments that work through entirely different mechanisms than conventional antidepressants.
What Is Treatment-Resistant Depression?
The most commonly used clinical definition of treatment-resistant depression is major depressive disorder (MDD) that has failed to respond adequately to at least two antidepressant trials of adequate dose and duration (typically 6–8 weeks at a therapeutic dose). Some definitions require failures from two different pharmacological classes.
It is important to distinguish TRD from undertreated depression – depression that has not responded because the treatment was at an insufficient dose, duration, or was not actually taken consistently. A thorough clinical evaluation is essential before concluding that depression is truly treatment-resistant.
Validated staging tools – such as the Thase-Rush Antidepressant Treatment History Form (ATHF) – can help clinicians assess the degree of treatment resistance and guide next-step decisions.
Why Do Some People Have Treatment-Resistant Depression?
Biological Factors
Several biological factors may contribute to inadequate antidepressant response:
- Pharmacogenomic variation: Genetic variants in CYP450 enzymes (the liver enzymes responsible for metabolizing many medications) can result in either too-rapid or too-slow metabolism of antidepressants – leading to either insufficient drug levels or toxic levels at standard doses
- Inflammatory pathways: Elevated inflammatory markers are documented in a subgroup of people with depression who show poor antidepressant response; anti-inflammatory approaches may be more effective for this subgroup
- HPA axis dysregulation: Chronic stress response activation may maintain depressive neurobiology in ways that conventional antidepressants do not fully address
Diagnostic Factors
TRD may sometimes reflect not true treatment resistance but rather a diagnostic factor that has not been addressed:
- Unrecognized bipolar depression – antidepressants alone are generally not effective for bipolar depression and may worsen the course of illness
- Unidentified co-occurring anxiety disorders – anxiety significantly complicates depression treatment
- Unrecognized PTSD – trauma-related depression responds poorly to antidepressants alone without trauma processing
- Unaddressed thyroid dysfunction, sleep apnea, or other medical conditions that directly contribute to depressive symptoms
Psychosocial Factors
Ongoing trauma exposure, chronic stress, relational difficulties, and social isolation all maintain depressive states in ways that medication cannot fully address. Psychosocial treatment is not optional for TRD – it is essential.
Diagnosing the Root of Treatment Resistance
Effective treatment of TRD begins with understanding why the depression has not responded. This requires comprehensive evaluation, which may include:
- Pharmacogenomic testing – genetic testing that identifies how a person’s body metabolizes psychiatric medications, helping guide more precise medication selection
- Full psychiatric evaluation to rule out misdiagnosis (particularly bipolar spectrum conditions)
- Medical workup to identify contributing physical conditions
- Trauma assessment – recognizing whether unprocessed trauma is driving the depression
- A comprehensive clinical assessment report that integrates findings into an individualized treatment recommendation
Evidence-Based Treatment Options for TRD
Medication Optimization
For many people with TRD, the answer is not a completely different treatment but rather medication optimization – adjusting doses, switching to different medication classes, or adding augmentation agents (such as lithium, atypical antipsychotics, or thyroid hormone). Pharmacogenomic testing can significantly improve the precision of this process.
Spravato (Esketamine)
Spravato (esketamine) is an FDA-approved nasal spray specifically indicated for treatment-resistant depression in adults. It is a glutamate NMDA receptor antagonist – an entirely different mechanism from conventional antidepressants – and it can produce rapid antidepressant effects, sometimes within hours of the first treatment. Spravato is administered in a certified healthcare setting with monitoring and is not available as a take-home medication.
dTMS / TMS
Deep transcranial magnetic stimulation (dTMS) is FDA-cleared for major depressive disorder. It uses focused magnetic pulses to stimulate underactive neural circuits in the left dorsolateral prefrontal cortex – a region consistently shown to be hypoactive in depression. It is non-invasive, requires no anesthesia, and has no systemic side effects. A typical course involves 20–36 sessions over 4–6 weeks.
Neurofeedback
Neurofeedback is an evidence-based adjunctive approach that trains brain wave patterns associated with depression – including excess slow-wave (theta) activity and deficits in alpha activity in the left frontal lobe. It is used as part of a comprehensive treatment plan, not as a standalone treatment.
Ketamine Infusion
Intravenous (IV) ketamine is an off-label treatment – meaning it is not FDA-approved for depression, though its use is supported by clinical evidence. It shares a mechanism with Spravato (both are NMDA receptor antagonists) but is administered differently. Any consideration of IV ketamine should involve consultation with an experienced clinician and transparent discussion of its off-label status.
Psychotherapy
Medication alone is consistently insufficient for TRD. Combined treatment – medication alongside evidence-based psychotherapy – produces better outcomes than either alone. CBT, behavioral activation, and trauma-focused therapies are important components of TRD treatment.
Emerging and Investigational Approaches
Research is actively investigating several additional approaches for TRD. These are mentioned here as areas of active scientific inquiry – not as endorsed treatments:
- Psilocybin-assisted therapy: Early clinical trials show promise for treatment-resistant depression; FDA breakthrough therapy designation has been granted. This remains investigational and is not currently available as a standard clinical treatment.
- Deep brain stimulation (DBS) and vagus nerve stimulation (VNS): Neuromodulation approaches for the most severe, chronic cases of TRD – available at specialized centers
What Does Recovery from TRD Look Like?
Recovery from treatment-resistant depression is often a process rather than a single event. It is helpful to distinguish between response (a meaningful reduction in symptom severity, typically 50% or more) and remission (return to baseline functioning with minimal residual symptoms).
Many people with TRD achieve meaningful response with advanced treatments – significantly improved quality of life even if full remission is not immediate. For others, full remission becomes possible once the right combination of approaches is identified. The important truth is that TRD does not mean no treatment will ever work. It means the search continues with more sophisticated tools.
Frequently Asked Questions
How many antidepressants should I try before considering TRD?
The most common clinical threshold for TRD is failure to respond to two adequate antidepressant trials – meaning full therapeutic dose for 6–8 weeks each, from ideally different pharmacological classes. If two trials have not produced adequate response, a more comprehensive evaluation and consideration of advanced treatment options is appropriate. A psychiatrist or prescribing clinician can help evaluate treatment history and guide next steps.
Is TRD permanent?
No. Treatment resistance describes where a person is at a given point in time, not a permanent state. Many people who have not responded to multiple antidepressants achieve response or remission with treatments like Spravato, TMS, or through identification and treatment of underlying factors (pharmacogenomic, diagnostic, or psychosocial). The range of available options has expanded substantially in recent years.
Does Spravato really work?
Spravato received FDA approval based on clinical trials demonstrating significant reductions in depressive symptoms in people with treatment-resistant depression. Studies show it can produce rapid improvement – sometimes within hours to days of initial treatment. It is not effective for everyone, and results vary. It should be considered as part of a comprehensive treatment plan, not used in isolation.
Is there a test to predict antidepressant response?
Pharmacogenomic testing can identify how a person metabolizes specific medications – which can help avoid medications likely to be ineffective or poorly tolerated at standard doses. It provides meaningful information about medication selection but does not definitively predict response, as genetics is only one of many factors determining treatment outcome.
Advanced Care for Treatment-Resistant Depression
Synchrony Brain Health specializes in advanced interventions for treatment-resistant depression, including FDA-approved Spravato (esketamine) and FDA-cleared dTMS. Our clinical team provides comprehensive evaluation – including pharmacogenomic assessment – and individualized treatment planning for people who have not found adequate relief from conventional antidepressants. If you have been living with treatment-resistant depression, a consultation with a clinician experienced in TRD is the most important next step.
This article is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
Citations: Rush, A.J., et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry; FDA approval documentation for Spravato (esketamine); BrainsWay dTMS clinical data.
